Reports on the decision of the U.S. Food and Drug Administration to grant fast track designation for Virulizin, the experimental drug being developed by Lorus Technologies Inc. as of June 5, 2002.EBSCO_bspWall Street Journal Eastern Edition...
“Receiving fast track designation from the FDA for tulmimetostat inARID1A-mutated endometrial cancer underscores this investigational therapy’s potential in a patient population with limited treatment options,” said Tim Demuth, MD, PhD, chief research, and development officer at MorphoSys, in a...
Cullinan Oncology announced that the FDA has granted Breakthrough Therapy Designation for CLN-081 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring epidermal growth factor (“EGFR”) exon 20 i...
The FDA granted a priority review to a supplemental biologics license application (sBLA) for atezolizumab (Tecentriq) for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations and high PD-L1 expression (TC3/IC3 wild-type...
cancer has been labeled as a "silent killer" because it is normally asymptomatic in the early stages which implies that it is often diagnosed at a late stage when tumors are highly resistant to treatment modalities. This underscores the critical need for new and mor...
Overall, having an additional tool to treat prostate cancer could be beneficial for patients who have not had success with earlier treatment. Considering the prevalence of prostate cancer, providers may take comfort in the availability of treatment methods. As this treatment goes throug...
Pancreatic cancer patients also need additional treatment options," said Daniel D. Von Hoff, MD, professor at the Translational Genomics Research Institute in Phoenix, AZ, and City of Hope, and now on the scientific advisory board for Diakonos Oncology.1 The DECIST trial evaluating DCV...
The FDA has granted a priority review to atezolizumab for the treatment of patients with locally advanced or metastatic non–small cell lung cancer who express PD-L1 and have progressed after a platinum-containing regimen.
“We are very excited that our cell-free DNA methylation multi-cancer early detection technology has received FDA breakthrough device designation,” Yusheng Han, founder and chief executive officer of Burning Rock, said in a press release. “For cancer, early diagnosis and treatment are th...
The Importance of Payment Reform in Cancer Care Behind the Scenes of CAR T-Cell Therapy: The Role of the Pharmacist Students Create TikTok Informercial for AR Exam Glasses Impact of Value-Based Care in Oncology: Insights from COA 2024 Tailoring CLL Treatment: Managing Toxic...